Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
It is a triple agonist, meaning it activates GLP-1 (glucagon-like peptide-1), GIP (glucose- dependent insulinotropic polypeptide) and glucagon receptors making it one of the most comprehensive peptide candidates in obesity, insulin resistance and metabolic research
Both are evidence-based, regulated, and supported by ongoing clinical care from our pharmacy team
While the program offers medical oversight, it includes fewer structured tools for habit change or ongoing coaching compared to platforms centered on psychology and lifestyle change
Research suggests it may support significant weight loss while also improving blood sugar control, insulin sensitivity, and other metabolic markers, which is why it is being closely watched as a potential dual-purpose therapy
By 12 weeks , average weight loss ranges from 35% of initial body weight, with this figure increasing to 1015% or more by 612 months in responders, particularly with higher-dose formulations like semaglutide 2.4 mg (Wegovy)
Your provider can help determine which is appropriate for your needs
US$ 24.92
US$ 28.36
US$ 27.32
US$ 24.99
US$ 23.39
